A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Suspended
Study type
Interventional
Design
Randomized · Triple · Other
Enrollment
28estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Safety issue was identified in the Phase2b D7860C00006 study, evaluating AZD6793 in moderate to very severe COPD participants. D7860C00005 study is temporary halted to amend the design to reflect changes implemented in the ongoing D7860C00006 study
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-14 | actual | When the study began enrolling |
| Primary completion | 2026-06-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-18 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes Mellitus
Interventions
- Drug: AZD6793 — also filed as Active
- Drug: AZD6793 Placebo — also filed as Placebo
Primary outcome
what the primary-completion date above is the date OFMean glucose levels
measured Day 7
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed